Wen Wu, Xiangyan Huang. Ceftazidime-induced immune hemolytic anemia: a case report[J]. Blood&Genomics, 2023, 7(1): 71-73. DOI: 10.46701/BG.2023012023002
Citation: Wen Wu, Xiangyan Huang. Ceftazidime-induced immune hemolytic anemia: a case report[J]. Blood&Genomics, 2023, 7(1): 71-73. DOI: 10.46701/BG.2023012023002

Ceftazidime-induced immune hemolytic anemia: a case report

  • Drug-induced immune hemolytic anemia (DIIHA) is considered a rare condition. Nonsteroidal anti-inflammatory drugs and antineoplastic drugs are the main causes of DIIHA. An 86-year-old male patient with pulmonary infection was admitted to the 960th Hospital of the PLA Joint Logistics Support Force. The patient was treated with ceftazidime in addition to supportive treatment. A history of antibiotics intake and clinical and laboratory hemolysis features were considered to be key bases for DIIHA diagnosis. Clinicians need to be aware of and accurately diagnose this rare complication caused by commonly prescribed drugs to stop the use of causative drugs in time, and therefore, to prevent serious and sometimes fatal consequences.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return